Anupam Rasayan India Ltd logo

Anupam Rasayan India Ltd

ANURAS NSE

Key Fundamentals

MicrocapSpecialty ChemicalsChemicals
Market Cap
₹13,689 Cr
Volatility
Low Risk
P/E Ratio
78.86
EBITDA
₹525 Cr
Return on Equity
5.19%
Debt to Equity
0.56
Book Value
₹290.02
EPS
₹8.55
52W High
₹1,415
52W Low
₹1,045.2

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Anupam Rasayan India Ltd insights

48 extracted metrics + investor summaries across FY14–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

4
  • Stock is trading at 4.09 times its book value
  • Tax rate seems low
  • Company has a low return on equity of 4.60% over last 3 years.
  • Dividend payout has been low at 9.85% of profits over last 3 years

Growth Rate

Revenue Growth
63.30% ↗
Net Income Growth
27.02% ↗
Cash Flow Change
-151.04% ↘
ROE
-9.11% ↘
ROCE
-11.11% ↘
EBITDA Margin (Avg.)
-22.66% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 8d ago
AI opinion · based on fundamentals
Risk high

Anupam Rasayan India Ltd is a specialty chemicals company with a market cap of Rs 13,810 crore, trading at a PE of 62.1x and a price-to-book of 4.18x. The company has demonstrated strong TTM sales growth of 65% and profit growth of 82%, but carries a low 3-year average ROE of approximately 4.6% and minimal dividend payout of 9.85% of profits.

Bull Case 7
  • TTM revenue growth of 65% indicates a significant acceleration in top-line momentum compared to the 3-year sales CAGR of 14%
  • TTM profit growth of 82% demonstrates strong operating leverage and improving profitability on an annualized basis
  • 5-year compounded sales CAGR of 24% shows sustained long-term revenue expansion in the specialty chemicals space
  • 5-year compounded profit CAGR of 19% reflects consistent earnings growth over a meaningful period
  • Company is expected to deliver a good quarter, suggesting near-term earnings visibility remains intact
  • Stock CAGR of 11% over 5 years indicates the market has rewarded the business over the medium term
  • 5-year ROE averaging around 6% shows gradual improvement from a low base, with last year at 6%
Bear Case 8
  • PE ratio of 62.1x is significantly elevated, demanding sustained high growth to justify current valuation
  • 3-year average ROE of only 4.6% indicates poor capital efficiency relative to the premium valuation commanded
  • 3-year compounded profit CAGR of -2% shows that until the recent TTM surge, earnings growth was actually negative
  • Price-to-book of 4.18x is high for a company generating only 5-6% return on equity over 3-5 years
  • Dividend payout of just 9.85% of profits over 3 years with a yield of only 0.06% offers negligible income to shareholders
  • Low tax rate raises questions about sustainability of reported earnings if tax normalization occurs
  • ROE has remained stagnant at 5-6% over a 3-to-5-year horizon with no meaningful improvement trend despite revenue growth
  • Stock 1-year CAGR of only 8% suggests the market has already priced in much of the recent operational improvement

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2d ago
Headwinds 1
  • Net profit falls 11% YoY Aug 14

    Q1FY27 net profit attributable to owners declined 11% YoY to ₹386.39 million despite strong revenue growth, indicating margin pressure.

Positives 4
  • Revenue surges 35% YoY in Q1 Aug 14

    Consolidated revenue rose 35% YoY to ₹6,549.80 million in Q1FY27, showing strong topline momentum.

  • Long-term supply deal with Basquevolt Aug 14

    Signed Letter of Intent with Spain-based Basquevolt S.A. for long-term specialty chemical supply, though financial terms were not disclosed.

  • New COO appointed Aug 14

    Ravi Desai promoted to COO effective Aug 14, 2026. He has 20+ years of specialty chemicals experience and has been with the company since 2012.

  • Pharma acquisition via Mates Visa Jul 17

    Acquired 100% of Mates Visa Consultancy for ₹10,000 to act as a PAC for the Bliss GVS Pharma acquisition, signaling diversification intent.

Neutral 1
  • Q1FY27 earnings call hosted Aug 11

    Anupam Rasayan held its Q1FY27 earnings call on August 14, 2026 to discuss unaudited standalone and consolidated results.

TL;DR: Anupam Rasayan delivered strong 35% YoY revenue growth in Q1FY27 and is expanding partnerships (Basquevolt LOI) and diversifying into pharma (Bliss GVS). However, net profit declining 11% despite robust topline suggests rising costs or operational inefficiencies that need monitoring. The trend is improving on growth but margin trajectory will be the key watchpoint in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
386
392
296
401
254
294
390
500
486
731
512
636
655
Expenses
285
285
216
308
201
214
266
356
362
596
385
498
493
Operating Profit
101
107
79
93
53
80
124
144
124
136
127
137
162
OPM %
26%
27%
27%
23%
21%
27%
32%
29%
26%
19%
25%
22%
25%
Other Income
12
3
2
12
6
2
-4
6
5
8
2
3
13
Interest
18
20
25
26
22
27
32
31
36
36
35
42
49
Depreciation
19
20
20
21
21
22
29
31
31
32
34
43
56
PBT
77
71
36
58
16
34
59
88
63
76
60
56
70
Tax %
32%
31%
28%
30%
25%
10%
9%
29%
23%
24%
-1%
0%
27%
Net Profit
52
49
26
40
12
31
54
63
48
57
61
56
51
EPS in Rs
3.59
3.78
1.68
2.82
0.36
1.52
2.56
4.05
3.1
3.9
4.31
3.75
3.39
Figures in ₹ Crores

Profit & Loss

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
502
529
811
1,074
1,602
1,475
1,437
2,365
2,535
Expenses
408
394
617
769
1,171
1,094
1,036
1,841
1,972
Operating Profit
93
135
194
305
431
381
401
525
563
OPM %
19%
25%
24%
28%
27%
26%
28%
22%
22%
Other Income
19
11
26
8
10
30
11
18
26
Interest
24
45
69
31
63
89
112
149
162
Depreciation
23
29
52
60
71
80
102
140
165
PBT
66
72
100
222
308
242
198
254
261
Tax %
24%
26%
30%
31%
30%
31%
19%
13%
—
Net Profit
49
53
70
152
217
167
160
222
225
EPS in Rs
9.85
10.64
7.04
15.18
16.83
11.71
8.49
14.94
15.35
Div. Payout %
0%
0%
7%
7%
15%
11%
9%
10%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
50
50
100
100
107
110
110
146
Reserves
432
515
1,473
1,627
2,265
2,651
2,740
3,188
Borrowings
694
847
423
836
822
1,069
1,373
1,867
Other Liabilities
146
252
301
327
584
772
1,045
2,811
Total Liabilities
1,323
1,664
2,298
2,891
3,778
4,602
5,269
8,013
Fixed Assets
681
977
1,115
1,202
1,417
1,501
2,185
3,713
CWIP
191
101
43
44
120
609
216
114
Investments
0
0
0
149
67
67
9
19
Other Assets
451
586
1,140
1,496
2,173
2,424
2,860
4,167
Total Assets
1,323
1,664
2,298
2,891
3,778
4,602
5,269
8,013
Figures in ₹ Crores

Cash Flow

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
39
95
1
-171
292
59
-30
334
Investing
-250
-178
-193
-412
-523
-392
-330
-820
Financing
206
102
416
384
371
395
223
621
Net Cash Flow
-6
19
224
-199
140
62
-137
135
Free Cash Flow
-209
-85
-144
-318
232
-644
-440
-220
CFO/OP
55
77
10
-44
84
28
3
72
Figures in ₹ Crores

Ratios

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
88
89
92
95
95
143
186
148
Inventory Days
277
515
530
852
483
627
876
490
Days Payable
105
226
215
225
167
247
348
261
Cash Conversion Cycle
260
379
408
722
410
524
715
377
Working Capital Days
56
21
168
218
153
138
160
111
ROCE %
—
9%
10%
11%
13%
9%
7%
7%

Shareholding Pattern

As of Jun 2026
Promoters 59.07%
Public 23.23%
Others 9.60%
FIIs 7.71%
DIIs 0.38%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Jul 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
65.40%
65.40%
65.40%
65.40%
65.18%
65.17%
65.16%
60.96%
60.81%
60.77%
60.73%
61.41%
61.26%
61.23%
61.23%
61.18%
61.18%
61.18%
59.07%
59.07%
59.07%
59.07%
59.07%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
9.13%
8.07%
7.14%
7.01%
7.45%
6.46%
4.94%
0.00%
7.63%
7.60%
6.91%
7.71%
DIIs
1.44%
2.00%
2.72%
3.15%
3.09%
3.95%
4.32%
6.19%
4.99%
3.74%
1.51%
2.51%
2.56%
2.65%
2.30%
2.32%
2.25%
2.24%
1.88%
1.37%
0.42%
0.35%
0.38%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
25.62%
23.71%
23.39%
22.73%
23.57%
24.05%
4.55%
4.69%
6.25%
5.90%
6.88%
24.37%
24.39%
25.94%
26.48%
26.23%
27.58%
25.54%
25.20%
24.89%
24.78%
23.93%
23.23%
Others
7.55%
8.90%
8.50%
8.72%
8.16%
6.83%
25.97%
28.17%
27.95%
29.59%
30.88%
2.58%
3.72%
3.04%
2.98%
2.82%
2.53%
6.11%
13.84%
7.03%
8.12%
9.74%
9.60%
No. of Shareholders
0
57
77,371
71,454
60,629
65,071
65,870
71,492
66,507
61,504
61,129
60,089
57,623
62,218
63,866
60,938
57,478
47,711
48,524
48,785
47,469
43,475
42,776

Documents

Frequently Asked Questions about Anupam Rasayan India Ltd

What does Anupam Rasayan India Ltd do?
Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries.[1]
Where is Anupam Rasayan India Ltd (ANURAS) listed?
Anupam Rasayan India Ltd is listed on the Indian stock exchanges. It is listed on NSE: ANURAS and BSE: 543275. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Anupam Rasayan India Ltd belong to?
Anupam Rasayan India Ltd operates in the Chemicals sector within the Specialty Chemicals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Anupam Rasayan India Ltd?
Anupam Rasayan India Ltd has a market capitalisation of approximately ₹13689.12 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Anupam Rasayan India Ltd?
The Price-to-Earnings (PE) ratio of Anupam Rasayan India Ltd is 78.86. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Anupam Rasayan India Ltd?
Over the past 52 weeks, Anupam Rasayan India Ltd has traded between a low of ₹1,045.2 and a high of ₹1,415. This range helps investors understand the stock's price volatility and recent trading levels.
Does Anupam Rasayan India Ltd pay dividends?
Yes, Anupam Rasayan India Ltd has a dividend yield of 0.06%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Anupam Rasayan India Ltd?
Anupam Rasayan India Ltd has a Return on Equity (ROE) of 5.19%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Anupam Rasayan India Ltd on Tapetide?
On Tapetide, you can view Anupam Rasayan India Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries.[1]

Website anupamrasayan.com
CEO Mr. Gopal Puranmal Agrawal
Employees 2,606
Listed 2021-03-24
Face Value ₹ 10
Issued Size 11,38,48,310

Explore More

More in Chemicals → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List